Callio Therapeutics
Manufacturing · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1201 3rd Ave Ste 2200, Seattle, Washingt...Website
www.calliotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Callio Therapeutics
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.Explore more
Callio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Callio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Callio Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Callio Therapeutics has new funding data
Click to see if Callio Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Callio Therapeutics
Earning: See what the market has to say on Callio Therapeutics recently announced quarterly report
Check if Callio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Callio Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Callio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Callio Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Callio Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Callio Therapeutics.
Callio Therapeutics financials insights
Gather financial insights about Callio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$187M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Callio Therapeutics News & Media
Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumorsSingapore: Callio Therapeutics launches with US$187m Series A - Investors in Healthcare
Callio Therapeutics launches with US$187m Series A
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Callio Therapeutics
Sign Up For FreeTo access detailed company insights
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.... Read More
